Abiopharma

🔍 VARKI PAUL (Executive)

Company: Avalo Therapeutics, Inc. (AVTX)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 62,500 shares of Common Stock at $13.43 per share (Direct)
  Date: 2026-05-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 66,134.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 12,563 shares of Common Stock at $8.04 per share (Direct)
  Date: 2026-05-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 78,697.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 37,375 shares of Common Stock at $18.912 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,322.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,196 shares of Common Stock at $19.7812 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 36,126.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 22,839 shares of Common Stock at $21.2155 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,287.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 9,253 shares of Common Stock at $22.6985 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,034.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 400 shares of Common Stock at $23.71 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,634.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 62,500 shares of Stock Option (Right to Buy) at $13.43 per share (Derivative)
  Date: 2026-05-06 | Code: M | Expires: 2034-06-24 | equity_swap_involved: 0 | shares_owned_after: 87,500.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 12,563 shares of Stock Option (Right to Buy) at $8.04 per share (Derivative)
  Date: 2026-05-06 | Code: M | Expires: 2035-01-28 | equity_swap_involved: 0 | shares_owned_after: 87,437.00 | transaction_form_type: 4 | Footnotes: F1, F7

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
• F2: The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F3: The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F4: The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F5: The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F6: Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.
• F7: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.